Table 3 Summary of meta-analysis results for overall survival
Analysis | No. of studies | HR (95% CI) | Heterogeneity | ||
|---|---|---|---|---|---|
Fix | Random | I2 (%) | p | ||
Overall pooled result | 42 | 0.940 (0.888–0.995) | 0.875 (0.784–0.976) | 64.40 | 0.000 |
Data resource | |||||
The included studies | 11 | 1.050 (0.941–1.172) | 0.667 (0.438–1.016) | 85.70 | 0.000 |
TCGA data | 21 | 0.89 (0.830–0.956) | 0.880 (0.810–0.956) | 21.60 | 0.183 |
SurvMicro GSE | 10 | 1.005 (0.825–1.224) | 0.971 (0.747–1.261) | 33.60 | 0.139 |
Human system | |||||
Urinary system | 3 | 0.947 (0.776–1.156) | 0.938 (0.708–1.244) | 43.40 | 0.171 |
Endocrine System | 4 | 0.828 (0.618–1.111) | 0.774 (0.406–1.474) | 61.90 | 0.049 |
Reproductive system | 4 | 0.791 (0.661–0.947) | 0.791 (0.661–0.947) | 0.00 | 0.560 |
Digestive system | 11 | 0.844 (0.738–0.965) | 0.821 (0.672–1.003) | 49.00 | 0.033 |
Nervous system | 2 | 1.08 (0.919–1.270) | 1.080 (0.919–1.270) | 0.00 | 0.906 |
Respiratory system | 8 | 0.855 (0.723–1.011) | 0.872 (0.611–1.244) | 69.80 | 0.002 |
Other | 10 | 1.036 (0.942–1.140) | 0.895 (0.688–1.164) | 79.60 | 0.000 |
Tumour type | |||||
HNSC | 2 | 0.734 (0.572–0.941) | 0.648 (0.376–1.116) | 61.90 | 0.105 |
GC | 4 | 0.668 (0.530–0.841) | 0.535 (0.327–0.877) | 64.40 | 0.038 |
BRCA | 4 | 0.828 (0.618–1.111) | 0.774 (0.406–1.474) | 61.90 | 0.049 |
NSCLC | 7 | 0.848 (0.715–1.006) | 0.853 (0.578–1.260) | 73.90 | 0.001 |
AML | 2 | 1.055 (0.818–1.362) | 0.971 (0.378–2.492) | 92.40 | 0.000 |
Overall pooled result |  | 0.816 (0.737–0.904) | 0.762 (0.614–0.945) | 71.30 | 0.000 |